Figure 1From: Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritisEvolution of disease activity score (DAS) (three variables) in 25 individual rheumatoid arthritis patients before (T0) and 12 weeks after (T12) initiation of adalimumab therapy. Patients are categorized into (good or moderate) responders or non-responders according to European League Against Rheumatism criteria.Back to article page